Lung Cancer | Specialty

Dr. Raffit Hassan on Avelumab in Unresectable Mesothelioma

October 12th 2015

Raffit Hassan, MD, Co-Chief Thoracic and Gastrointestinal Oncology Branch, Senior Investigator Head, Thoracic and Solid Tumor Immunotherapy Section at the Center for Cancer Research, National Cancer Institute, discusses a recent phase IB trial investigating avelumab in unresectable mesothelioma.

Three FDA Approvals and Two Priority Reviews

October 9th 2015

FDA Expands Nivolumab Lung Cancer Approval

October 9th 2015

Acting 3 months ahead of schedule, the FDA approved nivolumab for patients with nonsquamous non–small cell lung cancer previously treated with platinum-based chemotherapy.

Utility of PD-L1 Status as a Predictive Biomarker

October 8th 2015

Checkpoint Inhibition Continues Rapid Advance in Non-Small Cell Lung Cancer

October 6th 2015

Naiyer A. Rizvi, MD, discusses the future outlook for PD-1/PD-L1 checkpoint agents in non-small cell lung cancer and the potential for immunotherapy combinations.

Dr. David Ettinger Discusses the Road Ahead for Immunotherapy in NSCLC

October 6th 2015

David S. Ettinger, MD, discusses recent advancements in NSCLC, specifically with immunotherapy, and explains challenges that have stemmed from these developments.

FDA Approves Pembrolizumab for PD-L1-Positive Lung Cancer

October 2nd 2015

The FDA approved pembrolizumab (Keytruda) as a treatment for patients with pretreated advanced non­–small cell lung cancer across all histologies whose tumors express PD-L1.

2015 European Cancer Congress Highlights

October 2nd 2015

Changing Treatment Landscape in Advanced Lung Cancer

October 1st 2015

Role of Gefitinib in EGRF-Mutant NSCLC

October 1st 2015

EGFR-Resistant Disease in Lung Cancer

October 1st 2015

Benefits of Liquid Biopsies in Lung Cancer

October 1st 2015

LUX-Lung 8: Afatinib Survival Benefit in Squamous NSCLC

October 1st 2015

Activity of Afatinib in Lung Cancer

October 1st 2015

Checkpoint Inhibition Squamous Cell and Nonsquamous Cell NSCLC

October 1st 2015

Applying Immunotherapy Learnings in Melanoma to Lung Cancer

October 1st 2015

Immunotherapy: Potential for Higher Cure Rates in Lung Cancer

October 1st 2015

CAR T-Cell Therapy in Lung Cancer

October 1st 2015

Looking Ahead to the Next Game-Changer in Lung Cancer

October 1st 2015

FDA Grants Priority Review to Rociletinib for T790M-Positive NSCLC

September 30th 2015

The FDA has granted a priority review designation to rociletinib for patients with EGFR T790M-mutant metastatic non–small cell lung cancer following prior administration of an EGFR TKI.